Evolving concepts in the treatment of venous thromboembolism: The role of factor Xa inhibitors

Pharmacotherapy

Volumn 24, Issue 7 II, 2004, Pages

  Nutescu, Edith A ^a   Helgason, Cathy M ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Anticoagulants; Factor Xa inhibitors; Fondaparinux; Heparin; Treatment options; Venous thromboembolism; Warfarin

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CELL PROTEIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NAPSAGATRAN; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FETUS MALFORMATION; HUMAN; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; REVIEW; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBIN III; CLINICAL TRIALS; HUMANS; POLYSACCHARIDES; PULMONARY EMBOLISM; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 3042765724     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.10.82S.36121     Document Type: Review

References (32)

1. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991;151:933-8.
2. Zamorski MA, Opdycke RC. Advances in the prevention, diagnosis and treatment of deep venous thrombosis. Am Fam Physician 1993;47:457-69.
3. Rooke TW, Osmundson PJ. Heparin and the in-hospital management of deep venous thrombosis: cost considerations. Mayo Clin Proc 1986;61:198-204.
4. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-73.
5. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998;339:93-104.
6. Jansen MC, Haenen JH. Clinical and haemodynamic sequelae of deep venous thrombosis: retrospective evaluation after 7-13 years. Clin Sci (Colch) 1997;93:7-12.
7. Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992;327:1485-9.
8. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(suppl 1):S176-93.
9. Hirsh J, Fuster V. Guide to anticoagulant therapy. I. Heparin. American Heart Association. Circulation 1994;89:1449-68.
10. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(suppl 1):S64-94.
11. Turpie AGG, Chin BPS, Lip GYH. Venous thromboembolism: treatment strategies. BMJ 325;2002:948-50.
12. Weitz JI, Hirsh J. New anticoagulant drugs. Chest 2001; 119(suppl 1):S95-107.
13. Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-36.
14. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6.
15. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-82.
16. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-9.
17. Dolovich LP, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-8.
18. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
19. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(suppl 1):S8-21.
20. Nutescu EA, Wittkowsky AK. Direct thrombin inhibitors for anticoagulation. Ann Pharmacother 2004;38:99-109.
21. Nutescu E, Racine E. Traditional versus modern anticoagulant strategies: summary of the literature. Am J Health-Syst Pharm 2002;59(suppl 6):S7-14.
22. Turpie AGG, Gallus AS, Hoek JA, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344:619-25.
23. Herbert JM, Bernat A, Dol F, Herault JP, Crepon B, Lormeau JC. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J Pharmacol Exp Ther 1996;276:1030-103
24. Herbert JM, Petitou M, Lormeau JC. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997;15:1-26.
25. Peters PC Jr, Nutescu E, Andersen J. Wound pharmacobiology. Orthopedics 2003;26(suppl 8):S837-42.
26. Messmore HL Jr, Griffin B, Fareed J, Coyne E, Seghatchian J. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann NY Acad Sci 1989;556:217-32.
27. Ahmad S, Jeske WP, Walenga J. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999;5:259-66.
28. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin Thromb Hemost 2002;28(suppl 2):15-24.
29. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000;102:2726-31.
30. The Matisse Investigators. The Matisse-DVT trial, a randomized, double-blind study comparing once-daily fondaparinux with the low-molecular-weight heparin enoxaparin, twice-daily, in the initial treatment of symptomatic deep vein thrombosis. J Thromb Haemost 2003;(suppl 1):OC332.
31. Buller HR, Davidson BL, Decousus H, et al, for the Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702. (Erratum in N Engl J Med 2004;350:423.)
32. Buller HR, Davidson BL, Decousus H, et al, for the Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-702. (Erratum in N Engl J Med 2004;350:423.)